Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(24 sites)
United States
University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, California UCLA Department of Medicine-Hematology/Oncology, Los Angeles, California Sylvester Comprehensive Cancer Center, Miami, Florida University of Massachusetts Worcester, Worcester, Massachusetts START Midwest, Grand Rapids, Michigan Washington University School of Medicine - Siteman Cancer Center, St Louis, Missouri Memorial Sloan Kettering Cancer Center - Main Campus, New York, New York Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio Oregon Health & Science University, Portland, Oregon Fox Chase Cancer Center, Philadelphia, Pennsylvania Virginia Cancer Specialist, PC, Fairfax, Virginia Denmark
Aarhus University Hospital, Aarhus France
Centre Oscar Lambret, Lille Hôpital Européen Georges Pompidou, Paris Germany
Universitätsklinikum Eppendorf, Hamburg Italy
AOU Careggi - Padiglione 16 - Piano Terra - Ambulatori Oncologici - Ufficio Trial, Florence Istituto Europeo di Oncologia, Milan Netherlands
Antonie Van Leeuwenhoek Hospital, Amsterdam Portugal
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E., Porto Spain
Hospital Universitario Ramón y Cajal, Madrid Hospital Universitario Clinico San Carlos, Madrid Hospital Universitario Virgen Del Rocio, Seville Switzerland
Inselspital Universitätsklinikum Bern, Bern